Cargando…
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial
OBJECTIVES: As of December, 1(st), 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, resulted in more than 1 472 917 deaths worldwide and death toll is still increasing exponentially. Many COVID-19 infected people are asymptomatic or experience moderate symptoms and recover without med...
Autores principales: | Dioh, W., Chabane, M., Tourette, C., Azbekyan, A., Morelot-Panzini, C., Hajjar, L. A., Lins, M., Nair, G. B., Whitehouse, T., Mariani, J., Latil, M., Camelo, S., Lafont, R., Dilda, P. J., Veillet, S., Agus, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797700/ https://www.ncbi.nlm.nih.gov/pubmed/33430924 http://dx.doi.org/10.1186/s13063-020-04998-5 |
Ejemplares similares
-
A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality
por: Camelo, Serge, et al.
Publicado: (2021) -
A Phase 1 study for safety and pharmacokinetics of BIO101 (20‐hydroxyecdysone) in healthy young and older adults
por: Dioh, Waly, et al.
Publicado: (2023) -
BIOPHYTIS BIO101 IN SARCOPENIA: UPDATE ON THE SARA PROGRAM: FROM SARA-INT TOWARDS THE PHASE 3 STUDY
por: Tourette, Cendrine, et al.
Publicado: (2022) -
Developing new drugs that activate the protective arm of the renin–angiotensin system as a potential treatment for respiratory failure in COVID-19 patients
por: Latil, Mathilde, et al.
Publicado: (2021) -
Beyond AREDS Formulations, What Is Next for Intermediate Age-Related Macular Degeneration (iAMD) Treatment? Potential Benefits of Antioxidant and Anti-inflammatory Apocarotenoids as Neuroprotectors
por: Camelo, Serge, et al.
Publicado: (2020)